NBVG, IMDS, BRCO, BSDM, LUNA, CHIP OTCPicks.com Stocks to Watch for Tuesday, September 23rd

Our Stocks to Watch tomorrow include NutriPure Beverages Inc. (OTC: NBVG), Imaging Diagnostic Systems Inc. (OTCBB: IMDS), The Beard Co. (OTCBB: BRCO), BSD Medical Corp. (Nasdaq: BSDM), Luna Innovations Inc. (Nasdaq: LUNA) and VeriChip Corp. (Nasdaq: CHIP).

NUTRIPURE BEVERAGES INCORPORATED (OTC: NBVG)

"Up 330.00% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/NBVG.php

NutriPure Beverages, Inc. is bringing to market a complete line of premium bottled water products using a patented process that is more efficient and less costly than others currently in use. This unique process adds organic nutrients to water without adding masking flavors, colors or sweeteners, yielding premium enhanced water products that contain no calories, no carbohydrates, no colors and no extraneous flavors of any kind. The company intends to market a full line of water products to compete with currently available products including VitaminWater and SmartWater. Nu2O products will include a vitamin water, a weight loss formulation, an immune booster, an energy and fitness drink, and more. The company plans to launch its first Nu2O products in late 2009 and a total of 13-15 products within 12-15 months after the initial launch.

NBVG News:

September 22 - NutriPure Beverages, Inc. Secures Major Equipment Purchase in Preparation of Initial Product Launch

NutriPure Beverages, Inc. (OTC: NBVG) and its subsidiary XND Technologies, Inc. announced today that they have entered into a letter of intent to purchase a complete medical grade filling line from Langenberg Research in Eugene, Oregon, and has completed the financing arrangements necessary to expedite delivery. NutriPure will take possession of the equipment in the next few weeks, and it will be installed for use in the production of the Nu2O bottled water products. This move marks one of the final steps in the NutriPure's preparation for its initial product launch, and also adds a significant asset to the company's books. The company also announced that its updated financials are near completion and will be updated on PinkSheets within the next 7-10 days.

IMAGING DIAGNOSTIC SYSTEMS (OTCBB: IMDS)

"Up 111.11% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/IMDS.php

Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM® system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM®) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth. The Company is currently engaged in collecting clinical data to support the Premarket approval application for marketing clearance in the U.S. The FDA has determined that the Company’s clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States.

IMDS News:

September 22 - Imaging Diagnostic Systems Sells CTLM System in Malaysia

Imaging Diagnostic Systems, Inc. (OTCBB: IMDS), a pioneer in laser optical breast imaging systems, announced the sale of another CT Laser Mammography system in Asia. The system, which was sold to and installed at the Katherine Women’s Health Center in Malaysia, is currently being used in patient examinations. The Women’s Health Center will also serve as a training and demonstration site for future customers.

“We are getting very positive responses whenever we introduce the use of CTLM and believe that the CTLM will do very well in Malaysia and Brunei,” commented Christopher Su, Director of Daichi Holding Berhad, IDSI’s Malaysian agents.

The CTLM system was sold through Daichi Holding Berhad. The transaction was completed with the full balance wired to IDSI the week of September 14th. Daichi Holding Berhad is a equipment distributor with several years of experience serving as a representative for many companies and products.

“The first CTLM in Southeast Asia will not only introduce this new technology to the general public, but will also allow technologists, radiologists, and service engineers to become familiar with this emerging technology through the in-house training center,” stated Arthur Su, President of Daichi Holding Berhad. “This exposure will open the door for future CTLM sales in this region.”

THE BEARD COMPANY (OTCBB: BRCO)

"Up 109.46% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/BRCO.php

The Beard Company, through its subsidiaries, operates coal fines reclamation facilities in the United States. It operates in four segments: Coal Reclamation, Carbon Dioxide, e-Commerce, and Oil and Gas. The Coal Reclamation segment operates coal fines reclamation facilities; and provides slurry pond core drilling services, fine coal laboratory analytical services, and consulting services. The Carbon Dioxide segment produces carbon dioxide gas in Colorado and New Mexico. The e-Commerce segment offers a portfolio of Internet payment methods and security technologies that address payer and transaction authentication. The Oil and Gas segment engages in the exploration, development, production, and sale of oil and gas. This segment owns non-operated working interests or overriding royalty interests in producing wells in Colorado and Wyoming; and undeveloped oil and gas leases in such states and in Mississippi. The company was founded in 1921 and is headquartered in Oklahoma City, Oklahoma.

BRCO News:

September 21 - Geohedral LLC Reports Expanded Holdings and Significant Gold Discovery in Southeastern Alaska

The Beard Company (OTCBB: BRCO) announced that Geohedral LLC, a private company in which Beard has a 23.16% equity interest, has expanded its holdings of mining claims in the Yakutat Forelands district of southeastern Alaska to encompass 521 new claims (10,420 acres). The additional claims are located in the Tanis Mesa area and are contiguous to the 48,000-acre block that Geohedral staked and claimed last year (the "BlackSands Area").

Dr. P. Jan Cannon, Manager and President of Geohedral, reported: "At least 400 of the new claims are considered to be potential 'pay dirt,' and are underlain with an unconsolidated placer deposit that averages more than six feet in thickness and may average more than 12 feet in thickness. Thirty holes were dug or drilled across a widely spaced grid of points, with a spacing of one-half mile, across the central part of the staked area. Depth of the holes ranged from 2.5 feet to 27.1 feet below the surface. The 171 samples from these holes were assayed for gold, silver, platinum and palladium."

"An additional 30 shallow holes, mostly three to six feet in depth, were dug with a closer spacing of points in two selected parts of the widely spaced grid north and south of Tanis Mesa. These holes produced an additional 71 samples that were also assayed for gold, silver, platinum and palladium. Ten samples from the 30 holes were assayed for a suite of 14 elements. They provided a test of the previous assay values and an indication of the larger potential of the placer material."

"Two slim core holes were drilled on the south side of Tanis Mesa, one to 12.0 feet and the other to 50.3 feet, that produced 91 samples. All of the 353 samples were acquired, processed and assayed under strict chain-of-custody procedures."

"Preliminary evaluation of the assays indicates that the unconsolidated materials above the bedrock in the Tanis Mesa area contain appreciable amounts of gold and silver, averaging 0.30 oz/ton of gold and 0.75 oz/ton of silver. The 400 claims of primary interest are projected to produce 34,800,000 troy ounces of gold. In our opinion, we have a 'world class' discovery," Dr. Cannon concluded.

Herb Mee, Jr., Beard's President, added: "To put things into perspective, ENGINEERING AND MINING JOURNAL, a leading industry publication, defines a significant gold discovery as one 'containing at least 2 million oz. of gold in total reserves and resources.' So you can see why we are extremely excited about this new development."

"Geohedral is already contacting certain major players in the mining industry to determine whether they would be interested in becoming Geohedral's partner in the Tanis Mesa area. Some preliminary contacts have been made, and two parties have already expressed interest in obtaining additional information. Our goal is to sell a portion of Tanis Mesa to an industry partner, generating a meaningful return on our investment, while leaving Geohedral with sufficient funds to participate in the mining of Tanis Mesa and pursue further development of the BlackSands Area."

"We feel that Geohedral has a unique property to present to potential industry partners. Tanis Mesa is distinctive because of its location on the Gulf of Alaska, its temperate climate, its proximity to markets and ocean transportation, its abundance of water, and the fact that the unconsolidated materials above the bedrock can be extracted by low-cost dredging with minimal environmental impact. The placer material can be recovered without the costly blasting, shoveling, crushing, removal, handling and disposal costs that more expensive hard rock mines are faced with. We believe that operating costs to recover the material at Tanis Mesa will be among the lowest in the mining industry."

BSD MEDICAL CORPORATION (NASDAQ: BSDM)

"Up 103.72% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/BSDM.php 

BSD Medical’s product line includes systems that have been strategically designed to offer a range of thermal treatment systems. The BSD-2000 Hyperthermia System is under investigational device restrictions in the U.S.

BSDM News:

September 22 - BSD Medical Reports News Briefing at Europe's Largest Cancer Congress: Hyperthermia and Chemotherapy Treatment Prolongs Survival of Sarcoma Cancer Patients

BSD Medical Corporation (Nasdaq: BSDM) reports that significant and “medical practice changing” clinical study results were the subject of a news briefing at Europe’s largest cancer congress, ECCO15 – ESMO34, which is being held September 20 to 24, 2009, in Berlin, Germany. A Phase III study, which utilized the BSD-2000 Hyperthermia System, demonstrated that patients with high risk soft-tissue sarcomas were 30% more likely to be alive and cancer free almost three years after starting treatment if targeted heat therapy (hyperthermia) was added to their chemotherapy treatment.

The press information stated that, “The study, which found that the addition of the innovative heat technique more than doubled the proportion of patients whose tumours responded to chemotherapy without increasing toxicity, is also the first to show that any treatment other than surgery followed by radiation can prolong survival of this type of patient.” The press release also stated that the results increase the case for intensifying the exploration of this type of treatment of other types of cancer. “These findings provide a new standard treatment option, and we believe they are likely to change the way many specialists treat these tumours,” said the study’s leader, Professor Rolf Issels, a professor of medical oncology at Klinikum Grosshadern Medical Center at the University of Munich in Germany, who presented the results at the ECCO-ESMO congress.

“But the implications of these findings are more far-reaching,” Prof. Issels said. “This is also the first clear evidence that targeted heat therapy adds to chemotherapy. We expect our findings will encourage other researchers to test the approach in other locally advanced cancers. Targeted heat therapy has already shown promise in recurrent breast and locally advanced cervical cancer in combination with radiation and studies; combining it with chemotherapy in other localised tumours such as those in the pancreas and rectum are ongoing.”

The Phase III study involved 341 patients who were treated at medical centers in Europe and in the United States. All patients had locally advanced soft tissue sarcomas and were at high risk of recurrence and spread. All patients were given chemotherapy before and after surgery and radiotherapy. Half of the patients were randomly given hyperthermia along with chemotherapy.

“The patients receiving the targeted heat therapy fared better on all outcome measurements,” Prof. Issels said. “Almost three years after starting treatment, they were 42% less likely to experience a recurrence of their cancer at the same site or to die than those who were getting chemotherapy alone, surviving an estimated 120 months before local progression of their disease, compared with an estimated 75 months. Similarly, the average length of time that patients remained disease free was 32 months in the group that got both treatments, compared with 18 months in the group that got chemotherapy alone – an improvement of 30%.”

ABOUT ECCO - ESMO

ECCO15 – ESMO34 is the Joint 15th Congress of the European CanCer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO). The co-branded multidisciplinary meeting is held every two years. The ECCO-ESMO press information, including press contact information, has been provided in its entirety at www.ecco-org.eu/page.aspx/1671 and at http://bsdmc.com/pdf/ECCO-ESMO_Sarcoma_Press_Release.pdf.

LUNA INNOVATIONS INCORPORATED (NASDAQ: LUNA)

"Up 47.59% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/LUNA.php

Luna Innovations Incorporated develops and manufactures new-generation products for the healthcare, telecommunications, energy and defense markets. Through its disciplined commercialization business model, Luna has become a recognized leader in transitioning science to solutions. Luna is headquartered in Roanoke, Virginia. Luna’s nanoWorks division, located in Danville, Virginia, is developing pharmaceutical products empowered by nanomaterials with applications in diagnostics and therapeutics. Luna’s exclusive carbon nanomaterials offer unique physical, chemical, thermal, magnetic, biological, optical and electronic properties that can be tailored to customer needs.

LUNA News:

September 18 - Luna Innovations Receives NASDAQ Notification Regarding Bid Price; Grace Period Granted Through March 15, 2010

Luna Innovations Incorporated (Nasdaq: LUNA), a company focusing on sensing & instrumentation and pharmaceutical nanomedicines, today announced that the Company has received a letter from The NASDAQ Stock Market indicating that because the bid price of the Company’s common stock closed below the minimum $1.00 per share threshold set forth in NASDAQ Listing Rule 5550(a)(2) for the prior 30 consecutive business days, the Company has been provided 180 calendar days, or until March 15, 2010, to regain compliance with the minimum bid price requirement. In addition, should the Company satisfy the criteria for initial listing on The NASDAQ Capital Market (except for bid price) as of March 15, 2010, the Company will be entitled to a second 180-calendar day period, through September 13, 2010, to regain compliance with the minimum bid price requirement. The Company will regain compliance with NASDAQ’s minimum bid price requirement if the bid price of its common stock closes at $1.00 or higher for a minimum of ten consecutive business days during the compliance period. This notice does not affect the Company’s listing on NASDAQ at this time.

As previously announced on September 8, 2009, the NASDAQ Listing Qualifications Panel determined to transfer the Company’s listing to The NASDAQ Capital Market and to continue the listing of the Company’s common stock subject to several conditions, including the Company’s emergence from Chapter 11 reorganization by December 31, 2009.

VERICHIP CORPORATION (NASDAQ: CHIP)

"Up 29.64% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/CHIP.php

VeriChip Corporation, headquartered in Delray Beach, Florida, markets its VeriMed™ Health Link System for rapidly and accurately identifying people who arrive in an emergency room and are unable to communicate. This system uses the first human-implantable passive RFID microchip, cleared for medical use in October 2004 by the United States Food and Drug Administration. For more information on VeriChip, call 1-800-970-2447, or e-mail info@verichipcorp.com.

CHIP News:

September 21 - VeriChip Corporation Granted Exclusive License for Patents Used in Virus Triage Detection System for H1N1 Virus

Virus Triage Detection System Being Developed in Conjunction with Partner, RECEPTORS, Will Help Process Patient Samples

VeriChip Corporation (Nasdaq: CHIP) (“VeriChip”) and its development partner RECEPTORS LLC, a technology company whose AFFINITY by DESIGN™ chemistry platform can be applied to the development of selective binding products, announced today that VeriChip has been granted an exclusive license to RECEPTORS' Patent No. 7,504,364 titled “Methods of Making Arrays and Artificial Receptors” and Patent No. 7,469,076 “Sensors Employing Combinatorial Artificial Receptors,” in their application to the development of the virus triage detection system for the H1N1 virus. The patents can also be applied to detection systems for other viruses and biological threats such as Methicillin-resistant Staphylococcus aureus (MRSA).

Last week, VeriChip announced its plans to fund its existing partnership with RECEPTORS to develop the virus triage detection system for the H1N1 virus. The companies have published a white paper entitled, "An Integrated Sensor System for the Detection of Bio-Threats from Pandemics to Emerging Diseases to Bioterrorism," which outlines the system's development and is available at www.verichipcorp.com.

Scott R. Silverman, Chairman and CEO of VeriChip, said, "In a short period of time following our announcement earlier this month that VeriChip has agreed to acquire Steel Vault Corporation (OTCBB: SVUL) and form PositiveID Corporation, we have been intently focused on maximizing our product portfolio and relationships in order to bring identification technologies and tools for consumers and businesses to market. Our strong balance sheet immediately positions us to invest in our partnership with RECEPTORS and we believe that receiving the exclusive license as it relates to this application of the '364 and '076 patents, which are the foundation of the virus triage detection system being developed with RECEPTORS, is a key step in the evolution of PositiveID."

ABOUT RECEPTORS LLC

RECEPTORS LLC is a private company based in Chaska, Minnesota. RECEPTORS' mission is to advance the diagnosis and treatment of disease and to enhance the health, safety, and quality of the global environment through the development and application of artificial receptor products for both research and industry. To achieve this mission, RECEPTORS focuses its individual and collective efforts, its commitment to excellence, and the power of its technology to develop innovative solutions that meet the unique needs of its customers and stakeholders.

OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it.

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing.

Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward-looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.

Disclosure: OTCPicks.com has not been compensated by any of the companies covered in this release.